Jennifer Kelly, DO
Endocrinology, Diabetes & Metabolism · South Burlington, VTNPI 1104867779
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Ascendis Pharma Endocrinology Inc accounts for 73.6% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $8,207, 6.6 times the $1,240 reported in 2019.
Across 16 payments — averaging $1305.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ascendis Pharma Endocrinology Inc$15K
- Revvity, Inc.$3K
- Radius Health, Inc.$1K
- Shire North American Group Inc$1K
- Corcept Therapeutics$17
Across 60 payments — averaging $2107.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$62K
- Takeda Pharmaceuticals U.S.A., Inc.$40K
- Ascendis Pharma Endocrinology Inc$13K
- Shire North American Group Inc$11K
What the payments were for
- Consulting fees$9,11044%
- Speaking & faculty fees$10,58451%
- Travel & lodging$6873%
- Food & beverage$4842%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ascendis Pharma Endocrinology Inc | 12 | $15,375 |
| Revvity, Inc. | 1 | $3,000 |
| Radius Health, Inc. | 1 | $1,250 |
| Shire North American Group Inc | 1 | $1,240 |
| Corcept Therapeutics | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few endocrinology, diabetes & metabolism providers in Vermontto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Teriparatide | 318 | $855,863 |
| ForteoTeriparatide | 113 | $508,255 |
| OzempicSemaglutide | 210 | $295,413 |
| MounjaroTirzepatide | 168 | $240,649 |
| JardianceEmpagliflozin | 89 | $131,759 |
| TymlosAbaloparatide | 42 | $113,034 |
| TrulicityDulaglutide | 68 | $88,041 |
| Levothyroxine Sodium | 265 | $50,039 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $48,149 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 23 | $37,773 |
| JanuviaSitagliptin Phosphate | 26 | $35,433 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $32,331 |
| Tresiba Flextouch U-100Insulin Degludec | 58 | $28,113 |
| RybelsusSemaglutide | 16 | $24,864 |
| ProliaDenosumab | 12 | $20,729 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Radius Health, Inc.Tymlos | $1,250 | $113,03442 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology, diabetes & metabolism providers in Vermonton file to place this against a meaningful peer group, so we don't.
Other endocrinology, diabetes & metabolism in South Burlington
- Matthew GilbertSouth Burlington$66K
- John LeahyBurlington$34K
- David GorsonBennington$5K
- Christina BordeauBurlington$1K
- John GlickBrattleboro$222
- Barbara O'MaraBerlin$139
- Samantha Steinmetz-WoodBurlington$101
- Tina KaderBurlington$70
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.